Sign In
Buy VERV
$11.13
+0 (+0%)
At Close: Oct 24, 2025
7 CRISPR Stocks With the Best Long-Term Potential
07:10pm, Monday, 30'th Jan 2023
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:20am, Thursday, 15'th Dec 2022
The growth-focused money manager is making moves.
Verve Therapeutics Stock Skids On The FDA's Long List Of Gene-Editing Concerns
09:22am, Monday, 05'th Dec 2022
The FDA has a bevy of safety concerns surrounding Verve's gene-editing approach to high cholesterol, leading VERV stock to dive Monday. The post Verve Therapeutics Stock Skids On The FDA's Long List O
Verve Therapeutics to Participate in Upcoming Investor Conferences
06:30am, Friday, 11'th Nov 2022
BOSTON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing med
Why Verve Therapeutics' Stock Dropped 26.33% on Monday
02:03pm, Monday, 07'th Nov 2022
A trial for the company's lead therapy was put on hold.
Why Is Verve Therapeutics (VERV) Stock Down 28% Today?
10:56am, Monday, 07'th Nov 2022
Verve Therapeutics (NASDAQ: VERV ) stock is taking a beating on Monday following bad news from the FDA. The unfortunate news for VERV shareholders is the FDA putting the company's VERVE-101 Investigat
Verve Crashes After FDA Halts Plan To Test Gene Editor In People
09:20am, Monday, 07'th Nov 2022
U.S. officials halted Verve's plan to begin testing in people a gene-editing approach to high cholesterol, leading VERV stock to crash. The post Verve Crashes After FDA Halts Plan To Test Gene Editor
Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates
09:03am, Monday, 07'th Nov 2022
Verve Therapeutics (VERV) delivered earnings and revenue surprises of -5.33% and 81.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Shares Of CRISPR-Focused Verve Therapeutics Just Took A Grim Turn
12:03pm, Monday, 31'st Oct 2022
Verve Therapeutics announced disappointing lab results for its CRISPR gene-editing approach to high cholesterol, and VERV stock skidded. The post Why Shares Of CRISPR-Focused Verve Therapeutics Just T
These Were The Five Best And Worst Performing Mid-Cap Stocks In Q3 2022
09:21pm, Monday, 24'th Oct 2022
Mid-cap companies are those that fall between small and large cap companies. Thus, they are more stable than small-cap companies and, at the same time, offer higher growth opportunities than large-cap
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update
07:10am, Wednesday, 19'th Oct 2022 Seeking Alpha
ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. Click to see the firm's trades for Q3 2022.
Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About "DeeperPocketed" Competition
07:49pm, Thursday, 06'th Oct 2022 Benzinga
Credit Suisse has initiated coverage on Verve Therapeutics Inc (NASDAQ: VERV) with a Neutral rating and a $48 target price.
Its lead assets are VERVE-101 for heterozygous familial hypercholester
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
02:25pm, Thursday, 06'th Oct 2022 Benzinga
Upgrades
According to JP Morgan, the prior rating for RPM International Inc (NYSE:RPM) was changed from Neutral to Overweight. In the first quarter, RPM International showed an EPS of $1.47, compared
5 Top Stocks Cathie Wood Is Buying This Week
04:44pm, Friday, 30'th Sep 2022
Last week, Cathie Wood made headlines after it was announced that she would relinquish her position as portfolio manager over two of her exchange-traded funds (ETFs), the 3D Printing ETF (BATS: PRNT )
